Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound bismuth potassium citrate is a fixed-dose combination pharmaceutical product primarily used for the eradication of *Helicobacter pylori* infection and the treatment of associated gastrointestinal conditions such as duodenal ulcers. The combination typically consists of bismuth potassium citrate, tinidazole, and clarithromycin. Bismuth potassium citrate acts as a mucosal protective agent by forming a barrier over ulcer sites and exhibits direct antibacterial activity against *H. pylori*. Tinidazole is a nitroimidazole antimicrobial that causes DNA strand breakage in anaerobic bacteria, while clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This combination is frequently evaluated in clinical trials alongside proton pump inhibitors (PPIs) like omeprazole to achieve high eradication rates in patients with active peptic ulcer disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound bismuth potassium citrate.